破发股三元生物二股东拟减持2022年上市超募26.5亿

Core Viewpoint - Shandong Luxin Qisheng Investment Management Co., Ltd. (Luxin Capital), a major shareholder of Sanyuan Bio (301206.SZ), has reduced its stake by over 1%, resulting in a total reduction of 5% in its shareholding [1][3]. Shareholding Changes - Luxin Capital has reduced its holdings from 24,780,000 shares (12.25%) to 14,672,350 shares (7.25%) between March 7, 2023, and December 10, 2024, through various trading methods [2][3]. - The total number of shares reduced by Luxin Capital amounts to 10,107,650 shares, which includes a recent reduction of 2,627,650 shares [2][3]. Company Background - Sanyuan Bio was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 10, 2022, with an initial public offering of 33.721 million shares at a price of 109.30 yuan per share [5]. - The stock reached a peak price of 146.00 yuan on its first trading day but is currently in a state of decline [6][7]. - The total funds raised from the IPO amounted to 3.686 billion yuan, with a net amount of 3.547 billion yuan after deducting issuance costs [8]. Financial Information - The company initially planned to raise 900 million yuan for projects including the annual production of 50,000 tons of erythritol and the construction of a technology center, but ultimately raised 2.647 billion yuan more than planned [9].